EXORPHIA Selected for Tokyo Strategic Innovation Project to Advance IVF Technology

EXORPHIA's Innovative Leap in IVF Technology

EXORPHIA, a biotechnology company headquartered in Chiyoda City, Tokyo, has recently been chosen for the Tokyo Strategic Innovation Promotion Project for the fiscal year 2025. This project, backed by the Tokyo Metropolitan Government, will provide funding up to 80 million yen to promote the development and implementation of a groundbreaking IVF additive derived from fallopian tube epithelial cell-derived extracellular vesicles (EVs).

Addressing the Need for Enhanced IVF Success Rates

As the demand for infertility treatment continues to rise due to the increasing participation of women in the workforce and the trend toward later childbirth, the significance of improving the success rates of in vitro fertilization (IVF) has become critical. Enhancing these rates directly addresses women's health challenges and contributes to solving the decreasing birthrate issue in Japan.

EXORPHIA’s innovative approach focuses on the microenvironment of the fallopian tubes where fertilized eggs develop. By utilizing extracellular vesicles derived from fallopian tube epithelial cells, the firm aims to recreate the 'fallopian tube-derived signals' necessary for improving IVF success rates dramatically. This novel IVF culture additive represents the world’s first of its kind, striving to establish a physiological culture environment that can significantly improve the chances of successful pregnancies.

Project Strengths and Future Prospects

EXORPHIA's project integrates advanced data analysis, optical sensing technologies, and clinical insights from external organizations with the firm’s existing expertise in EV purification and embryo culture. By elucidating effective EV characteristics, the company aims to solidify the technological foundation for infertility treatments.

In addition, by combining this grant with private investments, EXORPHIA plans to maximize the leverage of its research and development budget, accelerating the creation of globally competitive innovations in the field.

CEO Koji Kuchiishi’s Comments

Koji Kuchiishi, the CEO of EXORPHIA, expressed his gratitude for the recognition of their EV technology as a viable solution for women's health and decreasing birthrates. He stated, “We are honored to be acknowledged for our efforts. Together with strong partners, we will accelerate our R&D to bring new hope to patients struggling with infertility.”

Project Overview

- Project Name: Tokyo Strategic Innovation Promotion Project Fiscal Year 2025
- Development Support Theme: Medical and Health
- Research and Development Focus: Development of IVF additives derived from fallopian tube epithelial cell extracellular vesicles
- Project Duration: March 1, 2026 - February 28, 2029 (up to 3 years)

About EXORPHIA

EXORPHIA is a biotechnology venture focused on unlocking the potential of extracellular vesicle (EV) technology to provide innovative medical solutions.

- Company Name: EXORPHIA, Inc.
- CEO: Koji Kuchiishi
- Location: 6F Otemachi Building, 1-6-1 Otemachi, Chiyoda City, Tokyo
- Business Focus: Research and development in biotechnology based on extracellular vesicle technology.